Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I.
Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy ...
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in ...
Jemperli received FDA breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, following a Fast Track designation in January 2023. The designation aims to expedite development ...
Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results